PHILADELPHIA — Patients with obstructive hypertrophic cardiomyopathy who were treated with mavacamten for 1 year had improvements in left ventricular outflow tract gradients, symptoms and N-terminal pro-B-type natriuretic peptide, according to data presented at the American Heart Association Scientific Sessions.
“The PIONEER open-label extension study shows that the initial results observed in the phase 2 PIONEER-HCM study are sustained and durable, and, importantly, that mavacamten can reduce or eliminate the obstruction of the left ventricle without depressing ejection fraction,” Stephen B. Heitner, MD, director of the Hypertrophic Cardiomyopathy Clinic at Knight Cardiovascular Institute and assistant professor of medicine in the division of cardiovascular medicine at Oregon Health and Science University in Portland, told Healio.
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2019 Healio All Rights Reserved.